Generic medication utilization policies in the United States and Medicaid sustainability

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Pharmaceutical Health Services Research

• Publication date

  2015-03-01

• Fields of study

  Medicine, Economics, Political Science

• Identifiers
  DOI 10.1111/jphs.12084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Implications and Investigations of Pharmacy Benefit in the United States

  2013cited by this paper
• Corte Suprema degli Stati Uniti d’America, 28 giugno 2012, National Federation Of Independent Business, et al. v. Sebelius; Secretary of Health and Human Services, et al. [567 U. S. (2012)]

  2012cited by this paper
• Medicaid program; eligibility changes under the Affordable Care Act of 2010. Final rule, Interim final rule.

  2012cited by this paper
• The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money.

  2011cited by this paper
• An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.

  2011cited by this paper
• Discontinuation Rates and Health Care Costs in Adult Patients Starting Generic Versus Brand SSRI or SNRI Antidepressants in Commercial Health Plans

  2011cited by this paper
• The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population

  2011cited by this paper
• Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.

  2011cited by this paper
• Brand Name versus Generic Warfarin: A Systematic Review of the Literature

  2011cited by this paper
• Deaths: leading causes for 2008.

  2010cited by this paper
• Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation

  2010influential reference
• Does Medicare Have an Implicit Cost-Effectiveness Threshold?

  2010cited by this paper
• Medication adherence and use of generic drug therapies.

  2009cited by this paper
• The Impact of Prevention on Reducing the Burden of Cardiovascular Disease

  2008cited by this paper
• Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

  2008cited by this paper
• Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

  2008cited by this paper
• Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications

  2008cited by this paper
• Interruptions in Medicaid Coverage and Risk for Hospitalization for Ambulatory CareSensitive Conditions

  2008cited by this paper
• Effects of a Physician Office Generic Drug Sampling System on Generic Dispensing Ratios and Drug Costs in a Large Managed Care Organization

  2007cited by this paper
• Effect on Drug Utilization and Expenditures of a Cost-Share Change From Copayment to Coinsurance

  2007cited by this paper
• Clinical pharmacists and inpatient medical care: a systematic review.

  2006cited by this paper
• The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.

  2006cited by this paper
• Effect of generic-only drug benefits on seniors' medication use and financial burden.

  2006cited by this paper
• Role of pharmacist counseling in preventing adverse drug events after hospitalization.

  2006cited by this paper
• The effects of prescription drug cost sharing: a review of the evidence.

  2005cited by this paper
• States' control of prescription drug spending: a heterogeneous approach.

  2005cited by this paper
• Do drug samples influence resident prescribing behavior? A randomized trial.

  2005cited by this paper
• Evidence-based and value-based formulary guidelines.

  2004cited by this paper
• Economic implications of evidence-based prescribing for hypertension: can better care cost less?

  2004cited by this paper
• A strategy to reduce cardiovascular disease by more than 80%

  2003cited by this paper
• Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.

  2003cited by this paper
• Life course epidemiology

  2003cited by this paper
• Approaches to pharmacy benefit management and the impact of consumer cost sharing.

  2003cited by this paper
• Trends in socioeconomic health inequalities in the Netherlands, 1981–1999

  2002cited by this paper
• Effect of antihypertensive samples on physician prescribing patterns.

  2002cited by this paper
• Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis

  2002cited by this paper
• Employer drug benefit plans and spending on prescription drugs.

  2002cited by this paper
• Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization

  2001cited by this paper
• Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?

  2001cited by this paper
• Managing drug costs: the perception of managed care pharmacy directors.

  2000cited by this paper
• Comparing health inequality in men and women: prospective study of mortality 1986-96

  2000cited by this paper
• Income inequality and mortality: importance to health of individual income, psychosocial environment, or material conditions

  2000cited by this paper
• The effect of drug sampling policies on residents' prescribing.

  1998cited by this paper
• A higher prevalence of health problems in low income groups: does it reflect relative deprivation?

  1998cited by this paper
• Role of childhood health in the explanation of socioeconomic inequalities in early adult health.

  1998cited by this paper
• A Life Course Approach to Chronic Disease Epidemiology

  1998cited by this paper
• Variations in Medicaid Spending among States

  1997cited by this paper
• A Medicaid primer

  1996cited by this paper
• Drug Formulary Restrictions as a Cost-Containment Policy in Medicaid Programs

  1993cited by this paper
• A critical analysis of studies of state drug reimbursement policies: research in need of discipline.

  1993cited by this paper
• Health insurance and the demand for medical care: evidence from a randomized experiment.

  1987cited by this paper
• Medicaid: The Trade-Off Between Cost Containment and Access to Care

  1986cited by this paper
• The demand for prescription drugs as a function of cost-sharing.

  1985cited by this paper

• No citing papers are available for this paper.